SMT C1100 - A Phase 1b, Open-label, Single and Multiple Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Paediatric Patients With Duchenne Muscular Dystrophy

Summit Therapeutics4 sites in 1 country12 target enrollmentNovember 2013

ConditionsDuchenne Muscular Dystrophy

InterventionsSMT C1100

Overview

Phase: Phase 1
Intervention: SMT C1100
Conditions: Duchenne Muscular Dystrophy
Sponsor: Summit Therapeutics
Enrollment: 12
Locations: 4
Primary Endpoint: Safety and tolerability
Status: Completed
Last Updated: 11 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to determine whether increasing doses of SMT C1100 are safe, well tolerated and achieve appropriate blood levels in patients with Duchenne Muscular Dystrophy (DMD).

Detailed Description

Primary Objective: To determine the safety and tolerability of single and multiple oral doses of SMT C1100 in patients with Duchenne Muscular Dystrophy (DMD). Secondary Objectives: To determine the single and multiple oral dose pharmacokinetics of SMT C1100 and its metabolites in patients with DMD.

Registry

clinicaltrials.gov

Start Date

November 2013

End Date

July 2014

Last Updated

11 years ago

Study Type

Interventional

Study Design

Single Group

Sex

Male

Investigators

Sponsor

Summit Therapeutics

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Patients will be males of any ethnic origin with a genetic diagnosis of DMD.
•Children between 5 and 11 years of age.
•A parent/legal guardian must date and sign a written consent on behalf of the patient, according to International Conference on Harmonisation (ICH) and local regulations. This person must understand the contents of the consent, requirements of the study and have had an opportunity to review questions with a medically trained member of the site study team.
•The patient is willing to give verbal or written age appropriate assent to participate.
•For safety reasons, the patient's parent/legal guardian must have a good understanding of the English language, as this is the only language the consent/assent forms are written in, and understand the requirements for reporting of any adverse event to the Investigator.

Exclusion Criteria

•Enrollment or participation in any therapeutic clinical trial within the prior 3 months or 5 times the half-life (whichever is longer).
•Initiation or change (other than dose modifications for body weight) of systemic corticosteroid therapy within 2 months prior to the start of dose administration or discontinuation of corticosteroids within 30 days prior to the start of dose administration.
•Known hypersensitivity to the excipients of the study drug or a previous history of drug allergy.
•Use of the following therapies is prohibited during the study and for at least 5 half-lives prior to the start of dose administration: Inducers of cytochrome P450 CYP1A2 (eg, carbamazepine, phenytoin, primidone, rifampin, omeprazole, and barbiturates), and moderate and strong inhibitors of CYP1A2 (e.g., fluvoxamine, ciprofloxacin, enoxacin, mexiletine; propafenone, zileuton). Substrates of CYP1A2 with narrow therapeutic windows (e.g., tacrine, theophylline, methadone, mexiletine). Nicotine, including exposure to daily passive smoking to minimize cytochrome P450 CYP 1A induction. Chargrilled food, cruciferous vegetables, caffeine, tea, and any xanthine containing foods, and drinks are prohibited from 36 hours prior to check-in until final discharge from study. Herbal supplements and homeopathic preparations (unless approved by medical monitor).
•Need for mechanical ventilation.
•Non ambulatory.
•Any clinically significant acute illness within 4 weeks of the start of dose administration.
•Any co-morbidity that, in the opinion of the Investigator, increases the risk of participating in the study.
•Symptomatic cardiomyopathy that in the opinion of the Investigator prohibits participation in this study.
•Abnormality in the 12-lead ECG that, in the opinion of the Investigator, increases the risk of participating in the study.

Arms & Interventions

SMT C1100

Patients will be studied in 3 groups (Groups A to C), with each group consisting of 4 patients aged between 5 to 11 years. It is planned that doses for Groups A to C will be administered in an escalating manner after safety review for each dose group.

Intervention: SMT C1100

Outcomes

Primary Outcomes

Safety and tolerability

Time Frame: After 10 days of treatment phase

To determine the safety and tolerability of single and multiple oral doses of SMT C1100 in patients with Duchenne Muscular Dystrophy (DMD) by assessing the participants adverse events, ECG results, vital signs and laboratory tests.